



University of Warwick institutional repository: <http://go.warwick.ac.uk/wrap>

This paper is made available online in accordance with publisher policies. Please scroll down to view the document itself. Please refer to the repository record for this item and our policy information available from the repository home page for further information.

To see the final version of this paper please visit the publisher's website. Access to the published version may require a subscription.

Author(s): Chi-Tin Shih, Stephen A. Wells, Ching-Ling Hsu, Yun-Yin Cheng & Rudolf A. Römer

Article Title: The interplay of mutations and electronic properties in disease-related genes

Year of publication: 2012

Link to published article:

<http://dx.doi.org/10.1038/srep00272>

Publisher statement: None



# The interplay of mutations and electronic properties in disease-related genes

Chi-Tin Shih<sup>1</sup>, Stephen A. Wells<sup>2</sup>, Ching-Ling Hsu<sup>3</sup>, Yun-Yin Cheng<sup>1</sup> & Rudolf A. Römer<sup>2</sup>

SUBJECT AREAS:

COMPUTATIONAL  
BIOLOGY

NANOBIOTECHNOLOGY

BIOPHYSICS

BIOINFORMATICS

<sup>1</sup>Department of Physics, Tunghai University, 40704 Taichung, Taiwan and The National Center for Theoretical Sciences, 30013 Hsinchu, Taiwan, <sup>2</sup>Department of Physics and Centre for Scientific Computing, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK, <sup>3</sup>Department of Physics, Chung-Yuan Christian University, 32023 Chung-Li, Taiwan.

Received  
10 June 2011

Accepted  
16 January 2012

Published  
15 February 2012

Electronic properties of DNA are believed to play a crucial role in many phenomena in living organisms, for example the location of DNA lesions by base excision repair (BER) glycosylases and the regulation of tumor-suppressor genes such as p53 by detection of oxidative damage. However, the reproducible measurement and modelling of charge migration through DNA molecules at the nanometer scale remains a challenging and controversial subject even after more than a decade of intense efforts. Here we show, by analysing 162 disease-related genes from a variety of medical databases with a total of almost 20,000 observed pathogenic mutations, a significant difference in the electronic properties of the population of observed mutations compared to the set of all possible mutations. Our results have implications for the role of the electronic properties of DNA in cellular processes, and hint at the possibility of prediction, early diagnosis and detection of mutation hotspots.

Correspondence and requests for materials should be addressed to C.T.S. (ctshih@thu.edu.tw) or R.A.R. (r.roemer@warwick.ac.uk).

Cells tend to accumulate over time genetic changes such as nucleotide substitutions, small insertions and deletions, rearrangements of the genetic sequences and copy number changes<sup>1</sup>. These changes in turn affect protein-coding or regulatory components and lead to health issues such as cancer, immunodeficiency, ageing-related diseases and other disorders. A cell responds to genetic damage by initiating a repair process or programmed cell death<sup>2</sup>. In recent years, a vast number of detailed databases have been assembled in which rich information about the type, severity, frequency and diagnosis of many thousand of such observed mutations has been stored<sup>3–6</sup>. This abundance of data is based on the now standard availability of massively parallel sequencing technologies<sup>7</sup>. Harvesting these genomic databases for new cancer genes and hence potential therapeutic targets has already demonstrated its usefulness<sup>8</sup> and several recent international cancer genome projects continue the required large-scale analysis of genes in tumours<sup>9</sup>.

The possible relevance of charge transport in DNA damage has recently also attracted considerable interest in the bio-chemical and bio-physical literature<sup>10–13</sup>. Direct measurement of charge transport and/or transfer in DNA remains a highly controversial topic due to the very challenging level of required manipulation at the nano-scale<sup>14</sup>. Ab-initio modelling of long DNA strands is similarly demanding of computational resources and so some of the most promising computational approaches necessarily use much simplified models based on coarse-grained DNA.<sup>11</sup> Here we compute and datamine the results of charge transport calculations based on two such effective models for each possible mutation in 162 of the most important disease-associated genes from four large gene databases. The models are (i) the standard one-dimensional chain of coupled nucleic bases with onsite ionisation potentials<sup>11,15</sup> as well as a novel 2-leg ladder model with diagonal couplings and explicit modelling of the sugar-phosphate backbone<sup>16</sup>.

## Results

**Point Mutations and Electronic Properties.** We consider native genetic sequences and mutations of disease-associated genes as retrieved from the *Online Mendelian Inheritance in Man* (OMIM)<sup>3</sup> of NCBI, the *Human Gene Mutation Database* (HGMD)<sup>4</sup>, the *International Agency of Research on Cancer* (IARC)<sup>5</sup> as well as *Retinoblastoma Genetics*<sup>6</sup>. We have selected these genes such that (i) those from OMIM have a well-known sequence with known phenotype as well as at least 10 point mutations, (ii) all other selected cancer-related genes have also at least 10 point mutations and (iii) all non-cancer related genes from HGMD have at least 200 point mutations (cp. Supplementary Table S1).

Many different types of mutation are possible in a genetic sequence including point mutations, deletion of single base pairs (producing a frame shift), and large-scale deletion or duplication of multiple base pairs. Here, we restrict our attention to point mutations as it allows us to directly compare the sequence before and after the



mutation. This leaves us with in total 19882 such mutations. We study the magnitude of the *change* in charge transport (CT) for pathogenic mutations when compared to all possible mutations either *locally*, i.e. at the given hotspot site, or *globally* when ranked according to magnitude of CT change. We find that the vast majority of mutations shows good agreement with a hypothesis where *smallest change in electronic properties* — as measured by a change in CT — corresponds to a mutation that has appeared in one of the aforementioned databases of pathogenic genes.

A gene with  $\mathcal{N}$  base pairs (bps) has a native nucleotide sequence  $(s_1, s_2, \dots, s_{\mathcal{N}})$  along the coding strand with  $s_i$  denoting one of the 4 possible nucleotide bases A, C, G, T. The gene has a total of  $3\mathcal{N}$  possible point mutations, which we denote as the set  $M_{\text{all}}$ , of which a subset  $M_{\text{pa}}$  are known pathogenic mutations. A point mutation is represented by the pair  $(k, s)$ , where  $k$  is the position of the point mutation in the genomic sequence and  $s$  is the mutant nucleotide which replaces the native nucleotide. We shall write a mutation from a native base P to a mutant base Q as “Pq”. We note that there are a total of twelve possible point mutations for each nucleotide position in a DNA sequence (from any one of four bases to any one of three alternatives). Of these twelve, four are *transitions*, in which a purine (A, G) base replaces a purine or a pyrimidine (C, T) replaces a pyrimidine, and eight are *transversions* in which purine is replaced by pyrimidine or vice versa. Biologically, transitions are in general much more common than transversions<sup>17</sup>. Indeed, the set of observed pathogenic mutations for our 162 genes contains 10999 transitions and 8883 transversions, whereas in the set of all mutations their ratio is by definition 1 : 2. The observed pathogenic mutations are thus already a biased selection from the set of possible mutations, favouring transitions. However, this local onsite chemical shift is not sufficient to fully explain our data as we will show later.

We compute and datamine the results of quantum mechanical transport calculations based on two effective Hückel models<sup>18</sup> for each possible mutation in those 162 genes. The models are (i) the standard one-dimensional chain of coupled nucleic bases with onsite ionisation potentials<sup>11,15</sup> as well as (ii) a novel 2-leg ladder model with diagonal couplings<sup>16</sup> and explicit modelling of the sugar-phosphate backbone<sup>19,22</sup>. Both models assume  $\pi$ - $\pi$  orbital overlap in a well-stacked double helix. The parameters are chosen to represent hole transport. Using the transfer matrix method<sup>20,21</sup> we calculate the spatial extent of (hole) wavefunctions of a given energy on a length of DNA with a given genetic sequence. Wavefunction localisation is directly related to conductance<sup>20</sup> and we therefore find it convenient to report our results in terms of conductance. For the specific models discussed here (for the novel 2-leg model, its precursor versions) a detailed study of the influence of the environment surrounding a DNA strand on charge migration has been presented previously<sup>22</sup>. It was shown that while the conductance results exhibited some quantitative differences, the main effect of the environment was an overall reduction which depends on the exact choice of the environment. However, such an overall effect is not a primary concern when CT *changes* are studied as in the present paper.

To determine the effect of a mutation, we consider sub-sequences of length  $L$  bps; there are  $L$  such sequences that include a given site  $k$ . For all  $L$  sequences we calculate quantummechanical charge transmission coefficients  $T$  (in units of  $e^2/h$ , averaged across a range of incident energies, as detailed in Methods) for the native and mutant sequences. We describe the effect of the mutation on the electronic properties of the DNA strand near to the mutation site using the mean square difference,  $\Gamma = \langle |T_{\text{native}} - T_{\text{mutant}}|^2 \rangle$ , averaged across all  $L$  sequences. Larger values of  $\Gamma$  therefore correspond to a greater difference in electronic structure between the native and mutant sequences. The length  $L$  must be long enough to allow for substantial delocalisation across multiple base pairs<sup>22</sup>, but should remain below the typical persistence length of  $\sim 150$  bps<sup>23</sup> such that any overlap or crossing by packing, e.g. by wrapping around histone complexes in

chromatin, can be ignored. In this study we have considered lengths of 20, 40, 60 bps. This requires, for each of the  $\mathcal{N}$  sites in a gene,  $L$  calculations for each sequence of length  $L$  and for each of 4 possible bases at that site; which, for the more than  $11 \times 10^6$  bases in our dataset of 162 genes, is more than  $5 \times 10^9$  quantum mechanical transport calculations.


**Local and global ranking.** We first compare  $\Gamma$  of each observed pathogenic mutation with the other two non-pathogenic ones at the same position and determine a *local ranking* (LR) of CT change. There are three possibilities of LR, namely *low*, *medium* and *high*. Note that those hotspots with more than one pathogenic mutations are excluded in the LR analysis. We have also sorted the LR ranking for each gene according to prevalence in Fig. 1(a+b). We find that for  $L = 20, 40$  and 60 the low CT change corresponds to 155 (95%), 148 (91%) and 140 (86%) of all 162 genes with pathogenic mutations. This is significantly above the 33% line expected for purely random DNA. Furthermore, the LR rankings cease their high values for low CT change upon randomly reordering the sequences. This indicates that it is indeed the fidelity of the sequence which gives rise to the observed low CT change (see examples of LR for the pathogenic mutations of *p16* and *CYP21A2* as well as the reordered *p16* in Supplementary Fig. S3).

We can also consider a *global ranking* (GR) by sorting CT change  $\Gamma$  for all possible  $3\mathcal{N}$  mutations of a gene with  $\mathcal{N}$  bps in order to get a ranking of *every* observed pathogenic mutation. By dividing each ranking by  $3\mathcal{N}$  we compute the normalised GR  $\gamma$  of the mutation, with values between 0 and 1. Smaller values of  $\gamma$  mean smaller CT change. By analogy to the local ranking, we divide the  $\gamma$  of the pathogenic mutations into three groups as before, i.e. low ( $\gamma < 33.3\%$ ), medium ( $33.3\% \leq \gamma < 66.7\%$ ), and high ( $\gamma \geq 66.7\%$ ) CT change. The results of the GR for the 162 genes are shown in the bottom row (c) and (d) of Fig. 1. As for the LR results, we observe many  $\gamma$  values with low CT change (cp. Supplementary Figs. S3 and S4). Hence the LR and GR results consistently show that observed pathogenic mutations are generally biased towards smaller change in CT than the set of all possible mutations (cp. Supplementary Fig. S5).

**Distributions of change in charge transport.** In Figure 2 we show as an example results for the distribution of  $\Gamma$  for the *p16* DNA strand for both 1D and 2-leg models. In panels (a+b), it is clear that the 111 observed pathogenic mutations of *p16* have on average *smaller changes* in the CT properties as compared to all possible 80220 mutations, for both the 1D and 2-leg models. We find that results for the vast majority of the other 161 genes are quite similar. The distributions of  $\Gamma$  values in Fig. 2(a+b) are approximately log-normal. We therefore calculate, for each of the 162 genes in our dataset, an average log  $\Gamma$  value for the distributions of all and pathogenic mutations. Histograms of the distributions of these  $\langle \log \Gamma \rangle$  values are shown in Fig. 2(c+d). It is once again clear that the distributions for observed pathogenic mutations are shifted towards lower  $\Gamma$  values in both the 1D and the 2-leg models.

We next define a *global CT shift* for a gene  $g$  as  $\Lambda_g = \langle \log \Gamma_{g,\text{all}} \rangle - \langle \log \Gamma_{g,\text{pa}} \rangle$ . Positive values of  $\Lambda_g$  indicate that the observed pathogenic mutations of gene  $g$  have a lower average  $\Gamma$ . For each of our 162 genes we obtain the distribution of  $\Lambda_g$  for the 1D and 2-leg models as shown in Figs. 2(e+f). We can define, for the whole set of 162 genes, an average global shift  $\bar{\Lambda} = \sum_g \Lambda_g / 162$ , weighting all genes equally; we can also weight the results by the number of observed pathogenic mutations for each gene  $|M_{\text{pa}}|_g$  for a *weighted* average global shift  $\tilde{\Lambda} = \frac{1}{\sum_g |M_{\text{pa}}|_g} \sum_g |M_{\text{pa}}|_g \Lambda_g$ . These values are also indicated in Figs. 2(e+f) and in both models there is a tendency towards *lower* average  $\Lambda_g$  for observed pathogenic mutations.

Therefore the LR and GR measures, studied for a variety of system sizes and two different models for DNA, show that the pathogenic mutations found in the databases are distinguished from the set of all



**Figure 1** | Sorted prevalence of the low, medium and high CT change among *local* (a+b) and *global* (c+d) rankings for pathogenic mutations in 162 genes using the 1D (a+c) and the 2-leg (b+d) models. Results are consistent for all three lengths  $L = 20, 40, 60$ . The  $1/3$  value expected by chance is shown as a dashed horizontal line. Low rankings are dramatically more prevalent locally and globally than chance would suggest.

possible mutations by a consistently smaller change in the electronic structure as measured by  $\Gamma$ . In Fig. 3, we present an average over all 12 LR and GR criteria and indicate the resulting agreement with the CT hypothesis for each gene. As the figure shows, 161 of 162 genes are above the no-signal (33%) line and hence show that for both 1D and 2-leg models and averaged over lengths 20, 40 and 60, a small CT change correlates with the existence and position of pathogenic mutations.


**Transitions and transversions.** In our models we would expect transitions to cause, in general, a smaller change in CT than transversions, as the change in onsite energy and in transfer coefficients is smaller for a transition than a transversion. However, as we will demonstrate here, the increased proportion of transitions among the observed pathogenic mutations is *not* sufficient to account for the distributions seen in Fig. 2.

In Fig. 4(a+b) we show the distribution of  $\Gamma$  values for our entire dataset of all  $\approx 34 \times 10^6$  possible mutations and 19882 known pathogenic mutations, dividing the datasets into transitions and transversions. For both models, the transitions are shifted to slightly lower  $\Gamma$  values than the transversions. However, in the 2-leg model, the distribution for observed pathogenic transitions appears co-located with the distribution for all transitions, and likewise for transversions. In the 1D model, by contrast, the observed pathogenic transitions are visibly shifted to lower  $\Gamma$  values than the set of all transitions, and the same is true for transversions.

In Fig. 4(c+d) we represent the distributions of  $\Gamma$  values for each of the twelve types of point mutation by points for the mean values of  $\log$

$\Gamma$  and bars indicating the standard deviation of the distribution of  $\log \Gamma$ . In the 2-leg model, the distributions for observed pathogenic mutations are essentially coincident with the distributions for all mutations for each type Pq. The positive  $\bar{\Lambda}$  and  $\bar{\Lambda}$  shift results in the 2-leg model are thus accounted for by the set of observed pathogenic mutations being biased towards transitions. The 1D model displays a quite different behaviour; in each case the mean of the distribution for the observed pathogenic mutations of any type Pq, lies from 7.5 to 20 standard errors *below* the mean for all possible mutations of type Pq. Hence the probability that the observed pathogenic mutations are a random subset of all mutations, with respect to their electronic properties in the 1D model, is comparable to the probability of drawing twelve values more than 7.5 standard deviations below the mean from a normal distribution, which is less than  $10^{-168}$ . The observed difference between CT change between observed pathogenic and all possible mutations is thus statistically highly significant irrespective of whether transitions or transversions are involved. In the 2D model, by contrast, the means of the  $\log \Gamma$  distributions for observed pathogenic mutations can lie either above or below those for all mutations for different types Pq, and the difference in the means — between 0.03 and 5.5 standard errors — is much smaller.

Let us also consider, for each gene  $g$ , simulation length  $L$  and each mutation type Pq whether the *subset shift*  $\lambda = \langle \log \Gamma_{\text{all}} \rangle - \langle \log \Gamma_{\text{pa}} \rangle_{g,L,Pq}$  is positive or negative. This gives us, for each model,  $162 \times 3 \times 12 = 5832$  data points, less 1029 cases where no calculation is possible as no pathogenic mutations of type Pq are known for gene  $g$ . These  $\lambda$  data are presented in Fig. 5. In the 2-leg model there are approximately equal numbers of negative and positive  $\lambda$  values. This



**Figure 2** | (a+b): Distribution of the change in charge transport  $\Gamma$  for pathogenic (orange bars) and all possible (cyan bars) mutations for the p16 (CDKN2A) gene with 26740 base pairs and 111 known pathogenic mutations. (c+d): Distribution of the average (logarithmic) change in charge transport ( $\log \Gamma$ ) for all pathogenic (orange bars) and all possible (cyan bars) mutations for all 162 genes. (e+f): Distribution of the global shift  $\Lambda$  values for all genes, showing a consistent tendency to positive values. The average  $\bar{\Lambda}$  (dashed) and weighted average  $\tilde{\Lambda}$  (dash-dotted) values are indicated by vertical lines similarly to the 0 line (dotted). The grey bars denote the error of mean for  $\langle \bar{\Lambda} \rangle$ . The results for the 1D and 2-leg models are displayed in panels (a,c,e) and (b,d,f), respectively. All results shown are for  $L = 40$ , data for  $L = 20$  and  $60$  are similar.


is consistent with a null hypothesis where the observed pathogenic mutations of a type Pq have the same distribution of  $\Gamma$  values as for all mutations of that type. In the 1D model, by contrast, such a null hypothesis is decisively rejected: there is a preponderance of positive  $\lambda$  values by 2.2 : 1 (3326 positive to 1513 negative) and the binomial probability of obtaining such a result at random would be approximately  $10^{-153}$ . The two analyses agree that observed pathogenic mutations display a significant bias towards smaller changes in electronic properties in the 1D model.

## Discussion


Our CT models act as probes of the statistics of the DNA sequence. It is possible that we are merely observing a correlation; i.e. that mutations are more likely to occur in areas of the genome with certain

statistical properties, for reasons not causally related to charge transport, and these properties correlate with biased CT properties in our 1D model. Such a correlation between quantum transport and mutation hotspots would in itself be a valuable and novel observation in bioinformatics. There are known chemical biases in the occurrence of mutations, such as the enhanced transition rate in C-G doublets<sup>24</sup>, the bias towards GC base pairs rather than AT pairs in biased gene conversion<sup>25,26</sup> and the tendency of holes to localise on GG and GGG sequences and there cause oxidative damage<sup>27</sup>. However, since our observed bias is consistent across all twelve types of point mutation, these known biases cannot fully account for our data.

There are also plausible causal connections between our data and cellular genetic processes where the electronic properties of DNA may be significant. One such process is gene regulation, where charge trans-



**Figure 3 | Graphs of the average over all LR and GR criteria (cp.Fig. S5).** The red data points and gene names correspond to an alphabetic ordering of genes, whereas the blue points and labels are ordered according to the magnitude of the average. A larger average denotes a better agreement with our hypothesis. Points which lie below the dashed 33% line show genes which on average fail. Results for HSD3B2 (unsorted) and ABCA4 (sorted) have been duplicated in both rows.




**Figure 4** | Distributions of  $\Gamma$  for the 1D (a) and 2-leg (b) models for all genes, with mutations divided into transitions and transversions. The distributions are normalised by the size of the mutation dataset. Lines are guides to the eye only. The means (symbols) and standard deviations (error bars) of the distributions of  $\log \Gamma$  are shown in panels (c) and (d) for the 1D and 2-leg models. *Estimated errors of the means are smaller than the symbols.* Distributions are shown for transition (Ti) and transversion (Tv) mutations, and for the twelve types of point mutation individually. Open symbols (blue, cyan) are for the set of all mutations, filled symbols (orange, red) for the set of pathogenic mutations.

port along the DNA strand can couple to redox processes in DNA-bound proteins, inducing protein conformational change and unbinding<sup>28</sup>. Similarly, it has been proposed that DNA repair glycosylases containing redox-active [4Fe-4S] clusters<sup>29</sup> may localise to the site of DNA lesions through a DNA-mediated charge transport mechanism<sup>30</sup>. The recognition of specific areas in the DNA sequence by DNA-binding proteins generally may involve electrostatic recognition of the target DNA sequence<sup>31</sup>. Furthermore, homologous recombination<sup>32</sup> — a process which is vital to the repair of double-strand breaks, a most serious DNA lesion<sup>33,34</sup>, and also to genetic recombination — relies on the mutual recognition of homologous chromosomes before strand invasion can occur. Homologous double-stranded DNA sequences are capable of mutual recognition even in a protein-free environment<sup>35</sup>, presumably via electronic or electrostatic interactions<sup>36–38</sup>.

All the above processes, especially those involving protein–DNA or DNA–DNA recognition, would be less disrupted by a smaller change in the electronic environment along the coding strand. From this point of view, the observed mutations are biased to cause *less* disruption to gene regulation and DNA damage repair in the cell. This may seem counterintuitive at first. However, in order for a mutation to appear in our dataset of pathogenic mutations, the cell and the organism must develop viably for long enough for a mutant phenotype to be observed. Mutations which cause large disruptions to DNA regulation and repair are more likely to be lethal to the cell at an early stage and will thus be absent from disease databases. Similarly, mutations which are more visible to DNA repair mechanisms are less likely to persist and to appear in databases.

Genetic repair and regulation mechanisms cannot know whether the consequences of a mutation are beneficial, neutral or harmful. We would therefore predict that neutral mutations should display the same bias, towards smaller change in electronic structure, as we observe in the pathogenic mutations. As a test of this prediction, we have considered the case of the TP53 gene, with 20303 base pairs and for which there are known 2003 pathogenic mutations, 366 silent mutations and 113 intronic mutations<sup>5</sup>. We have simulated these silent and intronic mutations using the 1D model. In Table 1 we analyze the statistical properties for the resulting  $\Gamma$  distributions; our results demonstrate that, for both transitions and transversions, the silent and intronic mutations are similar to the pathogenic mutations and significantly *disimilar* to the population of all possible mutations, as predicted. For completeness, histograms of the distribution of  $\Gamma$  values for these mutations are given in supplementary material, see Fig. S7.

In conclusion, we have performed a large-scale data mining analysis of mutation databases and find a correlation between the occurrence of mutations and the electronic structure underlying the charge transport calculations. This correlation is novel, but not necessarily unexpected as we argue above. As ours is inherently a statistical analysis, we have not been able to elucidate the causation behind the correlation. Even so, the knowledge that the change in electronic structure induced by mutations plays a role in fundamental biological and biochemical processes hints towards the possibility of electronic prediction, early diagnosis and detection of mutation hotspots.



**Figure 5 |** Distribution of subset shifts  $\lambda$  for the 2-leg (left) and 1D (right) models over all 162 genes split into the 12 possible mutations (Ac, Ag, At, Ca, ..., Tc, Tg). The capital letters on the bottom axes denote the original base pairs, whereas the lowercase letters in the top axes show the mutant base. The short red tick marks on the right axes distinguish different original bases. The system sizes  $L = 20, 40$  and  $60$  are shown in the left, centre and right column for each model. The orange shading corresponds to positive  $\lambda$  and blue to negative. The white squares correspond to cases for which either no corresponding pathogenic mutations are known (1029 cases) or for which the subset shift is inconclusive (3 cases for the 2-leg model).



**Table 1 | Mean logarithm of CT change  $\Gamma$  for gene TP53 using the 1D model with  $L = 20$ .** Data are divided into transition and transversions. We give standard errors of the mean (SEM) and standard deviations ( $\sigma$ ) for each distribution. From these we estimate the probability of each distribution being a random sample from the set of all mutations,  $p_{\text{all}}$ , or being a sample from a population similar to the pathogenic mutations,  $p_{\text{pa}}$  (cp. Fig. S7). There are 224 silent transitions and 142 silent transversions; 67 intronic transitions and 46 intronic transversions. The pathogenic mutations and all possible mutations outnumber the silent and intronic populations by factors of 10–1000 and so it is the SEM for the smaller populations that is significant. It is clear that the mean CT change  $\log_{10} \bar{\Gamma}$  for the silent and intronic populations is far more similar to the pathogenic populations than to the entire population of all possible mutations. This is true for both transitions and transversions, although the  $p$ -value for the intronic transitions is not statistically significant (i.e.  $\geq 0.05$ ) which we attribute to the small number of available intronic data.

	$\log_{10} \bar{\Gamma}$	SEM	$\sigma$	$p_{\text{all}}$	$p_{\text{pa}}$
All transitions	-1.753	0.003	0.427	-	-
Pathological transitions	-1.840	0.015	0.431	$1.01 \times 10^{-8}$	-
Silent transitions	-1.868	0.029	0.440	$6.62 \times 10^{-5}$	0.391
Intron transitions	-1.805	0.048	0.391	0.320	0.526
All transversions	-1.605	0.002	0.422	-	-
Pathological transversions	-1.710	0.012	0.4190	$< 10^{-10}$	-
Silent transversions	-1.691	0.036	0.432	0.016	0.610
Intron transversions	-1.739	0.054	0.337	-	0.636

## Methods

**Models of charge transport in DNA.** The simplest model of coherent hole transport in DNA is given by an effective one-dimensional Hückel-Hamiltonian for CT through nucleotide HOMO states<sup>11</sup>, where each lattice point represents a nucleotide base (A,T,C,G) of the chain for  $n = 1, \dots, N$ . In this tight-binding formalism, the on-site potentials  $\epsilon_n$  are given by the ionisation potentials  $\epsilon_G = 7.75\text{eV}$ ,  $\epsilon_C = 8.87\text{eV}$ ,  $\epsilon_A = 8.24\text{eV}$  and  $\epsilon_T = 9.14\text{eV}$ , at the  $n$ th site, cp. Fig. 6; the hopping integrals  $t_{n,n+1}$  are assumed to be nucleotide-independent with  $t_{n,n+1} = 0.4\text{eV}$ <sup>11</sup>. A model which is less coarse-grained is provided by the diagonal, 2-leg ladder model shown in Fig. 6. Both strands of DNA and the backbone are modelled explicitly and the different diagonal overlaps of the larger purines (A,G) and the smaller pyrimidines (C,T) are taken into account by suitable interstrand couplings<sup>16,39</sup>. The intra-strand couplings are  $0.35\text{eV}$  between identical bases and  $0.17\text{eV}$  between different bases; the diagonal inter-strand couplings are  $0.1\text{eV}$  for purine-purine,  $0.01\text{eV}$  for purine-pyrimidine and  $0.001\text{eV}$  for pyrimidine-pyrimidine. Perpendicular couplings to the backbone sites are  $0.7\text{eV}$ , and perpendicular hopping across the hydrogen bond in a base pair is reduced to  $0.005\text{eV}$ . For previous discussions leading to these choices of parameters as well as the influence of the environment on the charge migration properties of the models, we refer the reader to the existing literature<sup>11,12,22</sup>. We emphasise that we have checked the robustness of our results; for example, the results for *p53* do not change qualitatively when using either  $t_{n,n+1} = 0.1\text{eV}$  or  $1\text{eV}$  for the 1D model.

The 2-leg model<sup>16</sup> allows inter-strand coupling between the purine bases in successive base pairs, in accordance with electronic structure calculations<sup>39</sup>, and should therefore be a better model for bulk charge transport along the DNA double helix; the 1D model, by contrast, makes use of the site energies of only the bases on the coding strand<sup>15</sup>, and so is most representative of the electronic environment along that strand. We also find that the 2-leg model recovers some of the coding strand dependence of the 1D model upon decreasing the diagonal hoppings. For 28 genes, we find that reducing just the diagonal hopping elements


by a factor of two leads to a much greater agreement with the 1D results similar to Fig. 4(c).

**Calculation of quantum transmission coefficients.** The quantum transmission coefficient  $T(E)$  for a DNA sequence with length  $N$  bps for different injection energy  $E$  can be calculated for both models by using the transfer matrix method<sup>21,40</sup>. Let us define  $T_{j,L}(E)$  as the transmission coefficient for a part of a given DNA sequence which starts at base pair position  $j$  and is  $L$  base pairs long. The *position-dependent averaged transmission coefficient* at the  $k$ -th base pair for transmission length  $L$  bps is defined as

$$T_L^{(k)} = \frac{1}{L} \sum_{j=k-L+1}^k \frac{1}{E_1 - E_0} \int_{E_0}^{E_1} T_{j,L}(E) dE. \quad (1)$$

Here  $j$  ranges from  $k - L + 1$  to  $k$  such that each subsequence of length  $L$  contains the  $k$ th base pair.  $E_0$  and  $E_1$  are the lower and upper bounds of the incident energy of the carriers, e.g. for the 1D model used here, the values are  $5.75$  and  $9.75\text{eV}$ , respectively; for the 2-leg model the bounds are  $7$  and  $11\text{eV}$ . We have used an energy resolution of  $\Delta E = 0.005\text{eV}$ . Then we examine the difference between transmission coefficients of the normal and mutated genomic sequence of a point mutation<sup>15</sup> and hence denote by  $T_{j,L}^{(k,s)}$  the transmission coefficient of the same segment of DNA as  $T_{j,L}^{(k)}$  but with the point mutation  $(k, s)$ .  $T_L^{(k,s)}$  is the averaged effect of the point mutation  $(k, s)$  on CT properties for all subsequences of length  $L$  containing the mutation,

$$T_L^{(k,s)} = \frac{1}{L} \sum_{j=k-L+1}^k \int_{E_0}^{E_1} \frac{|T_{j,L}(E) - T_{j,L}^{(k,s)}(E)|^2}{E_1 - E_0} dE. \quad (2)$$



**Figure 6 | Schematic models for charge transport in DNA.** The nucleobases are given as circles (red, denoting pairs) and ellipses (blue, brown for single nucleotides). Electronic pathways are shown as solid lines of varying thickness to indicate variation in strength. Model (a) indicates the 1D model where the sugar-phosphate backbone is ignored. In model (b), brown circles denote the smaller pyrimidines, blue ellipses are the large purines and green circles denote the sugar-phosphate backbone sites. Note that diagonal hopping between purines is favoured, and between pyrimidines disfavoured, by the larger size of the purines.



1. Sherbet, G. V. *Genetic Recombination in Cancer* (Academic Press, 2003).
2. Frank, S. A. *Dynamics of Cancer: Incidence, Inheritance and Evolution*. Princeton Series in Evolutionary Biology (Princeton University Press, Princeton and Oxford, 2007).
3. McKusick-Nathans Institute of Genetic Medicine. Online Mendelian inheritance in man (2010). URL <http://www.ncbi.nlm.nih.gov/omim/>. Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD).
4. Steson, P. D. *et al.* Human gene mutation database (HGMD): 2003 update. *Hum. Mutat.* **21**, 577–581 (2003). URL <http://www.hgmd.cf.ac.uk/ac/index.php>.
5. Petitjean, A. *et al.* Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. *Hum. Mutat.* **28**, 622–29 (2007). <http://www-p53.iarc.fr/index.html>, R11.
6. Lohmann, D. R. & Gallie, B. A. L. Retinoblastoma: Revisiting the model prototype of inherited cancer. *Am. J. Med. Genet. C* **129C**, 23–28 (2005). <http://www.verandi.de/joomla>.
7. Nagl, S. (ed.) *Cancer Bioinformatics* (Wiley, Chichester, England, 2006).
8. Enkemann, S. A., McLoughlin, J. M., Jensen, E. H. & Yeatman, T. J. Whole-genome analysis of cancer. In Gordon, G. J. (ed.) *Cancer Drug Discovery and Development*, chap. 3, 25–55 (Humana Press, 2009).
9. The International Cancer Genome Consortium. International network of cancer genome projects. *Nature* **464**, 993–998 (2010).
10. Starikov, E. B., Lewis, J. P. & Tanaka, S. (eds.) *Modern Methods for Theoretical Physical Chemistry of Biopolymers* (Elsevier, Amsterdam, 2006).
11. Chakraborty, T. (ed.) *Charge Migration in DNA: Perspectives from Physics, Chemistry and Biology* (Springer Verlag, Berlin, 2007).
12. Berashevich, J. & Chakraborty, T. Mutational hot spots in DNA: where biology meets physics. *Physics in Canada* **63**, 103–107 (2007).
13. Genereux, J., Boal, A. & Barton, J. DNA-mediated charge transport in redox sensing and signalling. *J. Am. Chem. Soc.* **132**, 891–905 (2010).
14. Guo, X., Gorodetsky, A. A., Hone, J., Barton, J. K. & Nuckolls, C. Conductivity of a single DNA duplex bridging a carbon nanotube gap. *Nature Nanotechnology* **3**, 163 (2008).
15. Shih, C. -T., Roche, S. & Römer, R. A. Point-mutation effects on charge-transport properties of the tumor-suppressor gene p53. *Phys. Rev. Lett.* **100**, 018105 (2008).
16. Wells, S. A., Shih, C. -T. & Römer, R. A. Modelling charge transport in DNA using transfer matrices with diagonal terms. *Int. J. Mod. Phys. B* **23**, 4138–4149 (2009).
17. Collins, D. & Jukes, T. Rates of transition and transversion in coding sequences since the human-rodent divergence. *Genomics* **20**, 386–396 (1994).
18. Powell, B. J. *Computational Methods for Large Systems: Electronic Structure Approaches for Biotechnology and Nanotechnology*, chap. An introduction to effective low-energy Hamiltonians in condensed matter physics and chemistry (Wiley, Hoboken, 2011).
19. Cuniberti, G., Craco, L., Porath, D. & Dekker, C. Backbone-induced semiconducting behavior in short DNA wires. *Phys. Rev. B* **65**, 241314(R)–4 (2002).
20. Kramer, B. & MacKinnon, A. Localization: theory and experiment. *Rep. Prog. Phys.* **56**, 1469–1564 (1993).
21. Ndawana, M. L., Römer, R. A. & Schreiber, M. Effects of scale-free disorder on the Anderson metal-insulator transition. *Europhys. Lett.* **68**, 678–684 (2004).
22. Klotz, D. K., Römer, R. A. & Turner, M. S. Electronic transport in DNA. *Biophys. J.* **89**, 2187–2198 (2005).
23. Hegerman, P. J. Flexibility of DNA. *Ann. Rev. Biophys. Biophys. Chem.* **17**, 265–286 (1988).
24. Blake, R., Hess, S. & Nicholson-Tuell, J. The influence of nearest neighbors on the rate and pattern of spontaneous point mutations. *J. Mol. Evol.* **34**, 189–200 (1992).
25. Galtier, N. & Duret, L. Adaptation of biased gene conversion? extending the null hypothesis of molecular evolution. *TRENDS in Genetics* **23**, 273–277 (2007).
26. Marais, G. Biased gene conversion; implications for genome and sex evolution. *TRENDS in Genetics* **19**, 330–338 (2003).
27. Nunez, M., Holmquist, G. & Barton, J. Evidence for DNA charge transport in the nucleus. *Biochemistry* **40**, 12465–12471 (2001).
28. Augustyn, K. E., Merino, E. J. & Barton, J. K. A role for DNA-mediated charge transport in regulating p53: Oxidation of the DNA-bound protein from a distance. *Proc. Nat. Acad. Sci.* **104**, 18907–18912 (2007).
29. Boal, A., Yavin, E. & Barton, J. DNA repair glycosylases with a [4fe-4s] cluster: a redox cofactor for DNA-mediated charge transport? *J. Inorg. Biochem.* **101**, 1913–1921 (2007).
30. Yavin, E., Stemp, E. D. A., O’Shea, V. L., David, S. S. & Barton, J. K. Electron trap for DNA-bound repair enzymes: A strategy for DNA-mediated signaling. *Proc. Nat. Acad. Sci.* **103**, 3610 (2006).
31. Cherstvy, A., Kolomeisky, A. & Kornyshev, A. Protein-DNA interactions; reaching and recognizing the targets. *J. Phys. Chem. B* **112**, 4741–4750 (2008).
32. Ferguson, D. & Alt, F. DNA double strand break repair and chromosomal translocation: lessons from animal models. *Oncogene* **20**, 5572–5579 (2001).
33. Jackson, S. Sensing and repairing DNA double-strand breaks- commentary. *Carcinogenesis* **23**, 687–696 (2002).
34. Khanna, K. & Jackson, S. DNA double-strand breaks: signalling, repair and the cancer connection. *Nature Genetics* **27**, 247–254 (2001).
35. Baldwin, G. S. *et al.* DNA double helices recognize mutual sequence homology in a protein free environment. *J. Phys. Chem. B* **114**, 1060–1064 (2008).
36. Kornyshev, A. A. & Leikin, S. Sequence recognition in the pairing of DNA duplexes. *Phys. Rev. Lett.* **86**, 3666–3669 (2001).
37. Cherstvy, A. Positively charged residues in DNA-binding domains of structural proteins follow sequence-specific positions of DNA phosphate groups. *J. Phys. Chem. B* **113**, 4242–4247 (2009).
38. Cherstvy, A. DNA-DNA sequence homology recognition: physical mechanisms and open questions. *J. Mol. Recognit.* **24**, 283–287 (2010).
39. Rak, J., Voityuk, A., Marquez, A. & Rösch, N. The effect of pyrimidine bases on the holetransfer coupling in DNA. *J. Phys. Chem. B* **106**, 7919–7926 (2002).
40. Roche, S. Sequence dependent DNA-mediated conduction. *Phys. Rev. Lett.* **91**, 108101–4 (2003).

## Acknowledgements

This work was supported by the National Science Council in Taiwan (CTS, Grant No. 97-2112-M-029-002-MY3 and 100-2112-M-029-001-MY3) and the UK Leverhulme Trust (RAR, SAW, Grant No. F/00215/AH). Part of the calculations were performed at the National Center for High-Performance Computing in Taiwan. We are grateful for their help.

## Author contributions

CTS and RAR coordinated the international collaboration and wrote the main manuscript text. CTS, RAR and SAW wrote the programs and performed the main computation. YYC and CLH analyzed the source databases and performed the data preprocessing. All authors analyzed the data and reviewed the manuscript.

## Additional information

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare that they have no competing financial interests.

**License:** This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

**How to cite this article:** Shih, C., Wells, S.A., Hsu, C., Cheng, Y. & Römer, R.A. The interplay of mutations and electronic properties in disease-related genes. *Sci. Rep.* **2**, 272; DOI:10.1038/srep00272 (2012).